MarketPeel
Insider Trading Intelligence
Pricing
…
JZ

Jonathan Zalevsky

NKTR
CHIEF R&D OFFICER · NEKTAR THERAPEUTICS · CIK 0001789857
FILING MIX · LIFETIME33%/67%
BUYS
18
SELLS
37
TOTAL VALUE
$4.84M
COMPANIES
1
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
9,756
AVG SELL PX
$10.56
TRADE KIND
SHOWING 55 / 55
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
34 backtested trades · 8 horizons · 25 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Jonathan Zalevsky, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d34+50.00%+3.45%+0.03%+3.42%+0.10%1.22
14d34+55.88%+5.51%+0.07%+5.44%-1.79%1.15
30d34+61.76%+8.88%-0.33%+9.21%-4.57%1.24
60d34+50.00%+14.76%+1.28%+13.48%-4.15%1.52
90d34+50.00%+21.99%+3.70%+18.30%-1.39%1.74
180d34(2 pending)+53.13%+30.86%+7.28%+24.14%-19.98%1.24
1y34(9 pending)+60.00%+39.34%+16.47%+22.88%-61.73%—
2y34(14 pending)+80.00%+25.32%+29.69%-4.37%-95.47%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
NKTR · 9,756 shares · as of Jun 30, 2026
0102,850205,700308,549411,399202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 18 buys / 37 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
NKTR
NEKTAR THERAPEUTICS
SALE10b5-1
10b5-1 plan
5,681$70.00$397.7K9,756Jun 30, 2026Jul 2, 2026 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE10b5-1
10b5-1 plan
5,538$60.71$336.2K15,437Jun 15, 2026Jun 17, 2026 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
199$65.51$13.0K20,975May 19, 2026May 21, 2026 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
180$73.00$13.1K21,174Feb 18, 2026Feb 20, 2026 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE10b5-1
10b5-1 plan
3,867$35.67$137.9K21,354Jan 20, 2026Jan 22, 2026 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
25,000——25,000Dec 22, 2025Dec 23, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
6,250——25,221Dec 22, 2025Dec 23, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
1,157$54.28$62.8K18,971Nov 25, 2025Nov 25, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
2,666——20,128Nov 21, 2025Nov 25, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
4,766——4,766Nov 21, 2025Nov 25, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE10b5-1
10b5-1 plan
432$33.60$14.5K17,958Sep 4, 2025Sep 8, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE10b5-1
10b5-1 plan
307$35.69$11.0K17,462Sep 4, 2025Sep 8, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE10b5-1
10b5-1 plan
793$32.43$25.7K18,390Sep 4, 2025Sep 8, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE10b5-1
10b5-1 plan
189$34.41$6.5K17,769Sep 4, 2025Sep 8, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE10b5-1
10b5-1 plan
485$30.10$14.6K19,183Sep 2, 2025Sep 4, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
16,666——16,666Aug 19, 2025Aug 21, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
725$26.59$19.3K19,668Aug 19, 2025Aug 21, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
10,712$0.67$7.2K305,892May 19, 2025May 21, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
10,300$1.01$10.4K316,604Feb 19, 2025Feb 21, 2025 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
51,115$0.94$48.0K326,904Dec 19, 2024Dec 20, 2024 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
375,000——375,000Dec 13, 2024Dec 17, 2024 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
135,000——378,019Dec 13, 2024Dec 17, 2024 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
270,000——270,000Dec 13, 2024Dec 17, 2024 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
7,785$1.01$7.9K243,019Nov 19, 2024Nov 20, 2024 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
6,866$1.28$8.8K250,804Aug 19, 2024Aug 20, 2024 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
7,355$1.75$12.9K257,670May 17, 2024May 20, 2024 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
9,014$0.68$6.1K265,025Feb 20, 2024Feb 22, 2024 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
250,000——250,000Dec 13, 2023Dec 15, 2023 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
9,646$0.49$4.7K274,039Nov 17, 2023Nov 20, 2023 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
9,703$0.78$7.6K283,685Aug 16, 2023Aug 17, 2023 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
9,791$0.72$7.0K293,388May 16, 2023May 17, 2023 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
10,484$3.00$31.5K303,179Feb 16, 2023Feb 17, 2023 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
13,460$3.57$48.1K313,663Nov 16, 2022Nov 18, 2022 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
73,716$4.65$342.8K327,123Aug 18, 2022Aug 19, 2022 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
10,560$4.76$50.3K400,839Aug 16, 2022Aug 17, 2022 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
135,000——411,399Aug 15, 2022Aug 17, 2022 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
270,000——270,000Aug 15, 2022Aug 17, 2022 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
21,673$3.95$85.6K276,399May 16, 2022May 17, 2022 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
23,950——298,072May 15, 2022May 17, 2022 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
10,912$10.95$119.5K274,122Feb 16, 2022Feb 18, 2022 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
94,000——94,000Dec 16, 2021Dec 20, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
52,950——285,034Dec 16, 2021Dec 20, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
20,869$13.16$274.6K232,084Nov 16, 2021Nov 17, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
40,150——252,953Nov 15, 2021Nov 17, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
71,550——71,550Oct 12, 2021Oct 14, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
7,662$13.83$106.0K212,803Aug 16, 2021Aug 18, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
31,111$18.30$569.3K235,065May 17, 2021May 19, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
24,141$22.37$540.0K266,176Feb 16, 2021Feb 18, 2021 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
40,000——290,317Dec 18, 2020Dec 22, 2020 ↗View →
NKTR
NEKTAR THERAPEUTICS
PURCHASEGRANT
Stock grant
71,500——71,500Dec 18, 2020Dec 22, 2020 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
16,380$16.40$268.6K250,317Nov 23, 2020Nov 25, 2020 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
29,618$16.93$501.4K266,697Nov 16, 2020Nov 18, 2020 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
26,200$19.67$515.4K296,315Aug 17, 2020Aug 19, 2020 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
4,558$22.51$102.6K322,515May 18, 2020May 20, 2020 ↗View →
NKTR
NEKTAR THERAPEUTICS
SALE
Chief R&D Officer
4,774$22.35$106.7K327,073Feb 18, 2020Feb 20, 2020 ↗View →
Other insiders · NKTR
Loading peer insiders…
About this filer
CIK 0001789857
ROLE
Chief R&D Officer
PRIMARY
NKTR
COMPANIES
1
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001789857DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback